| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Malaria, Falciparum | 79 | 2026 | 224 | 17.160 |
Why?
|
| Plasmodium falciparum | 80 | 2026 | 250 | 14.990 |
Why?
|
| Antimalarials | 43 | 2026 | 127 | 9.240 |
Why?
|
| Drug Resistance | 43 | 2026 | 155 | 8.740 |
Why?
|
| Protozoan Proteins | 34 | 2025 | 129 | 6.140 |
Why?
|
| Malaria | 31 | 2026 | 153 | 6.080 |
Why?
|
| Artemisinins | 21 | 2026 | 41 | 5.900 |
Why?
|
| Burkitt Lymphoma | 16 | 2025 | 73 | 5.360 |
Why?
|
| Military Medicine | 22 | 2022 | 33 | 4.790 |
Why?
|
| Epstein-Barr Virus Infections | 11 | 2025 | 104 | 4.740 |
Why?
|
| Herpesvirus 4, Human | 14 | 2025 | 198 | 3.640 |
Why?
|
| High-Throughput Nucleotide Sequencing | 23 | 2025 | 313 | 3.250 |
Why?
|
| Antigens, Protozoan | 12 | 2025 | 59 | 3.170 |
Why?
|
| Mutation | 22 | 2026 | 2633 | 3.140 |
Why?
|
| Whole Genome Sequencing | 8 | 2026 | 84 | 2.320 |
Why?
|
| Genome, Viral | 4 | 2025 | 140 | 1.990 |
Why?
|
| Humans | 164 | 2026 | 64272 | 1.580 |
Why?
|
| Genetic Variation | 16 | 2025 | 387 | 1.540 |
Why?
|
| Military Personnel | 12 | 2022 | 120 | 1.540 |
Why?
|
| Selection, Genetic | 8 | 2025 | 83 | 1.470 |
Why?
|
| Malaria Vaccines | 5 | 2023 | 37 | 1.430 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2026 | 498 | 1.430 |
Why?
|
| Tanzania | 16 | 2026 | 39 | 1.290 |
Why?
|
| Wounds and Injuries | 11 | 2024 | 251 | 1.230 |
Why?
|
| Uganda | 17 | 2025 | 56 | 1.190 |
Why?
|
| Prevalence | 22 | 2026 | 1407 | 1.160 |
Why?
|
| Nanopores | 2 | 2025 | 14 | 1.150 |
Why?
|
| Child | 36 | 2026 | 4583 | 1.130 |
Why?
|
| Child, Preschool | 26 | 2026 | 2019 | 1.060 |
Why?
|
| MicroRNAs | 5 | 2023 | 696 | 1.050 |
Why?
|
| Afghan Campaign 2001- | 13 | 2017 | 70 | 1.040 |
Why?
|
| Malaria, Vivax | 7 | 2025 | 49 | 1.030 |
Why?
|
| Plasmodium ovale | 5 | 2026 | 9 | 0.970 |
Why?
|
| Human papillomavirus 16 | 1 | 2025 | 20 | 0.950 |
Why?
|
| Pyrimethamine | 11 | 2025 | 20 | 0.940 |
Why?
|
| Genotype | 17 | 2025 | 668 | 0.930 |
Why?
|
| Sulfadoxine | 9 | 2024 | 15 | 0.930 |
Why?
|
| Translocation, Genetic | 2 | 2024 | 71 | 0.910 |
Why?
|
| Viral Matrix Proteins | 1 | 2025 | 50 | 0.890 |
Why?
|
| Democratic Republic of the Congo | 11 | 2025 | 19 | 0.880 |
Why?
|
| Plasmodium vivax | 7 | 2025 | 47 | 0.880 |
Why?
|
| Traumatology | 6 | 2024 | 15 | 0.860 |
Why?
|
| Infant | 21 | 2025 | 1664 | 0.850 |
Why?
|
| Papillomavirus Infections | 1 | 2025 | 132 | 0.830 |
Why?
|
| Air Ambulances | 5 | 2016 | 32 | 0.830 |
Why?
|
| Haplotypes | 14 | 2026 | 134 | 0.770 |
Why?
|
| Kenya | 12 | 2026 | 93 | 0.750 |
Why?
|
| Parasites | 4 | 2023 | 16 | 0.740 |
Why?
|
| RNA, Viral | 3 | 2021 | 276 | 0.720 |
Why?
|
| Drug Combinations | 12 | 2024 | 168 | 0.690 |
Why?
|
| Female | 54 | 2026 | 33383 | 0.690 |
Why?
|
| Injury Severity Score | 7 | 2017 | 116 | 0.690 |
Why?
|
| Mosquito Vectors | 3 | 2026 | 15 | 0.670 |
Why?
|
| Genomics | 8 | 2024 | 379 | 0.670 |
Why?
|
| Diagnostic Tests, Routine | 5 | 2025 | 52 | 0.650 |
Why?
|
| Adolescent | 25 | 2026 | 6306 | 0.650 |
Why?
|
| Male | 49 | 2026 | 30322 | 0.630 |
Why?
|
| Evolution, Molecular | 6 | 2021 | 324 | 0.620 |
Why?
|
| Warfare | 7 | 2018 | 41 | 0.610 |
Why?
|
| Phylogeny | 10 | 2025 | 385 | 0.600 |
Why?
|
| DNA, Protozoan | 8 | 2025 | 50 | 0.590 |
Why?
|
| RNA, Messenger | 4 | 2022 | 1552 | 0.590 |
Why?
|
| Young Adult | 24 | 2026 | 4782 | 0.590 |
Why?
|
| Primates | 4 | 2014 | 55 | 0.580 |
Why?
|
| Gene Expression Profiling | 4 | 2023 | 783 | 0.570 |
Why?
|
| Adult | 36 | 2026 | 17136 | 0.570 |
Why?
|
| Folic Acid Antagonists | 3 | 2024 | 8 | 0.570 |
Why?
|
| Antigenic Variation | 1 | 2017 | 7 | 0.550 |
Why?
|
| Gene Frequency | 6 | 2025 | 123 | 0.550 |
Why?
|
| Gene Deletion | 5 | 2025 | 312 | 0.550 |
Why?
|
| Ethiopia | 4 | 2025 | 9 | 0.530 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 192 | 0.530 |
Why?
|
| Transportation of Patients | 3 | 2013 | 50 | 0.510 |
Why?
|
| Genotyping Techniques | 3 | 2025 | 21 | 0.510 |
Why?
|
| Software | 2 | 2018 | 388 | 0.480 |
Why?
|
| Genome, Protozoan | 5 | 2024 | 13 | 0.480 |
Why?
|
| Zambia | 6 | 2025 | 17 | 0.470 |
Why?
|
| Coinfection | 4 | 2025 | 58 | 0.460 |
Why?
|
| Rwanda | 5 | 2025 | 17 | 0.460 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 532 | 0.440 |
Why?
|
| Gene Duplication | 3 | 2006 | 34 | 0.440 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2013 | 184 | 0.440 |
Why?
|
| Parasitic Sensitivity Tests | 5 | 2025 | 15 | 0.440 |
Why?
|
| Critical Care | 3 | 2018 | 402 | 0.430 |
Why?
|
| Chloroquine | 7 | 2025 | 61 | 0.420 |
Why?
|
| Trauma Centers | 4 | 2022 | 127 | 0.420 |
Why?
|
| Asymptomatic Infections | 5 | 2025 | 29 | 0.420 |
Why?
|
| Bayes Theorem | 2 | 2025 | 123 | 0.410 |
Why?
|
| Laparoscopy | 1 | 2018 | 501 | 0.410 |
Why?
|
| Cross-Sectional Studies | 14 | 2025 | 2621 | 0.400 |
Why?
|
| HLA-DR alpha-Chains | 2 | 2026 | 7 | 0.390 |
Why?
|
| Cervix Uteri | 2 | 2025 | 61 | 0.390 |
Why?
|
| HIV-1 | 3 | 2025 | 725 | 0.390 |
Why?
|
| Plasmodium malariae | 4 | 2024 | 5 | 0.380 |
Why?
|
| Membrane Proteins | 1 | 2017 | 908 | 0.360 |
Why?
|
| Sarcoma, Kaposi | 2 | 2023 | 17 | 0.360 |
Why?
|
| United States | 22 | 2024 | 7923 | 0.360 |
Why?
|
| Blood Component Removal | 3 | 2016 | 16 | 0.360 |
Why?
|
| Prognosis | 3 | 2025 | 1769 | 0.350 |
Why?
|
| Amodiaquine | 3 | 2026 | 3 | 0.340 |
Why?
|
| Anopheles | 3 | 2026 | 23 | 0.340 |
Why?
|
| Communicable Diseases | 2 | 2022 | 91 | 0.340 |
Why?
|
| Introns | 4 | 2026 | 114 | 0.320 |
Why?
|
| Incidence | 5 | 2023 | 1386 | 0.320 |
Why?
|
| Polymorphism, Genetic | 4 | 2024 | 191 | 0.320 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2026 | 727 | 0.320 |
Why?
|
| Iraq War, 2003-2011 | 6 | 2016 | 66 | 0.310 |
Why?
|
| Hypocalcemia | 3 | 2018 | 19 | 0.310 |
Why?
|
| Parasitemia | 3 | 2024 | 47 | 0.300 |
Why?
|
| Vaccination | 3 | 2023 | 371 | 0.300 |
Why?
|
| Hospitals, Military | 3 | 2018 | 4 | 0.270 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2026 | 629 | 0.270 |
Why?
|
| Plasma Exchange | 2 | 2018 | 24 | 0.270 |
Why?
|
| Endemic Diseases | 4 | 2024 | 24 | 0.260 |
Why?
|
| Population Surveillance | 3 | 2018 | 209 | 0.260 |
Why?
|
| Malawi | 5 | 2022 | 11 | 0.260 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 437 | 0.260 |
Why?
|
| Genome | 3 | 2023 | 276 | 0.250 |
Why?
|
| Rh-Hr Blood-Group System | 2 | 2018 | 2 | 0.250 |
Why?
|
| Computational Biology | 2 | 2019 | 357 | 0.250 |
Why?
|
| Phenotype | 4 | 2025 | 1223 | 0.250 |
Why?
|
| Plateletpheresis | 2 | 2017 | 6 | 0.250 |
Why?
|
| Merozoite Surface Protein 1 | 4 | 2024 | 24 | 0.240 |
Why?
|
| Complement C4a | 1 | 2026 | 4 | 0.240 |
Why?
|
| Climate | 1 | 2026 | 6 | 0.240 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2006 | 38 | 0.240 |
Why?
|
| Animal Distribution | 1 | 2026 | 5 | 0.240 |
Why?
|
| Culicidae | 2 | 2023 | 12 | 0.240 |
Why?
|
| HIV Infections | 2 | 2025 | 976 | 0.240 |
Why?
|
| Celiac Disease | 1 | 2026 | 19 | 0.240 |
Why?
|
| Animals | 21 | 2026 | 20955 | 0.240 |
Why?
|
| War-Related Injuries | 2 | 2016 | 3 | 0.240 |
Why?
|
| Membrane Transport Proteins | 3 | 2025 | 136 | 0.240 |
Why?
|
| Transcriptome | 2 | 2021 | 396 | 0.240 |
Why?
|
| Biodiversity | 1 | 2026 | 40 | 0.240 |
Why?
|
| Leukocyte Reduction Procedures | 1 | 2025 | 3 | 0.230 |
Why?
|
| Dried Blood Spot Testing | 1 | 2025 | 4 | 0.230 |
Why?
|
| Seasons | 1 | 2026 | 138 | 0.230 |
Why?
|
| Asia, Southeastern | 1 | 2025 | 9 | 0.230 |
Why?
|
| Disease Eradication | 1 | 2025 | 6 | 0.230 |
Why?
|
| Calcium | 3 | 2018 | 580 | 0.230 |
Why?
|
| Alleles | 4 | 2023 | 449 | 0.230 |
Why?
|
| Microsatellite Repeats | 3 | 2024 | 41 | 0.230 |
Why?
|
| Inhibitory Concentration 50 | 4 | 2025 | 93 | 0.230 |
Why?
|
| Segmental Duplications, Genomic | 1 | 2024 | 2 | 0.220 |
Why?
|
| Molecular Probes | 2 | 2024 | 31 | 0.220 |
Why?
|
| Leukocytes | 1 | 2025 | 103 | 0.220 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2025 | 60 | 0.220 |
Why?
|
| Mining | 1 | 2024 | 4 | 0.220 |
Why?
|
| Urban Population | 1 | 2025 | 198 | 0.220 |
Why?
|
| Blood Group Antigens | 1 | 2024 | 6 | 0.220 |
Why?
|
| Drug Resistance, Multiple | 1 | 2024 | 32 | 0.220 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2025 | 146 | 0.210 |
Why?
|
| Sequence Analysis, DNA | 7 | 2025 | 417 | 0.210 |
Why?
|
| Middle Aged | 14 | 2026 | 17923 | 0.210 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 45 | 0.210 |
Why?
|
| Cell Line, Tumor | 2 | 2025 | 1494 | 0.210 |
Why?
|
| Polysaccharides | 1 | 2025 | 151 | 0.200 |
Why?
|
| Afghanistan | 2 | 2013 | 14 | 0.200 |
Why?
|
| Antibody Formation | 1 | 2023 | 114 | 0.200 |
Why?
|
| Herpesvirus 8, Human | 1 | 2023 | 17 | 0.200 |
Why?
|
| Blood Transfusion | 3 | 2022 | 162 | 0.200 |
Why?
|
| Cambodia | 6 | 2021 | 27 | 0.200 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 4 | 2024 | 22 | 0.190 |
Why?
|
| Cluster Analysis | 3 | 2018 | 263 | 0.190 |
Why?
|
| Proteasome Inhibitors | 1 | 2022 | 32 | 0.190 |
Why?
|
| Vaccines | 1 | 2024 | 98 | 0.190 |
Why?
|
| Deer | 1 | 2022 | 12 | 0.190 |
Why?
|
| Host-Pathogen Interactions | 2 | 2023 | 266 | 0.190 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2021 | 245 | 0.190 |
Why?
|
| Chagas Disease | 1 | 2022 | 37 | 0.190 |
Why?
|
| Insecticides | 1 | 2022 | 45 | 0.180 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 56 | 0.180 |
Why?
|
| Trypanosoma cruzi | 1 | 2022 | 53 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2001 | 10 | 0.180 |
Why?
|
| Viral Proteins | 2 | 2021 | 266 | 0.180 |
Why?
|
| Mosaicism | 1 | 2001 | 30 | 0.180 |
Why?
|
| Ghana | 4 | 2022 | 14 | 0.180 |
Why?
|
| Receptors, KIR | 1 | 2021 | 4 | 0.180 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 512 | 0.180 |
Why?
|
| Anemia | 1 | 2022 | 128 | 0.170 |
Why?
|
| Aminoquinolines | 1 | 2021 | 16 | 0.170 |
Why?
|
| Naphthoquinones | 1 | 2021 | 6 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 423 | 0.170 |
Why?
|
| Mucous Membrane | 1 | 2021 | 22 | 0.170 |
Why?
|
| Biomedical Research | 1 | 2024 | 270 | 0.170 |
Why?
|
| Air Microbiology | 1 | 2021 | 11 | 0.170 |
Why?
|
| Premedication | 2 | 2018 | 20 | 0.170 |
Why?
|
| Pregnancy | 8 | 2022 | 2370 | 0.170 |
Why?
|
| Air Pollution, Indoor | 1 | 2021 | 37 | 0.170 |
Why?
|
| Africa | 3 | 2025 | 29 | 0.170 |
Why?
|
| Penis | 1 | 2021 | 38 | 0.170 |
Why?
|
| Automobiles | 1 | 2021 | 66 | 0.170 |
Why?
|
| Cohort Studies | 7 | 2023 | 2605 | 0.170 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 2738 | 0.170 |
Why?
|
| Transplant Recipients | 1 | 2020 | 37 | 0.160 |
Why?
|
| Herpesviridae Infections | 1 | 2020 | 27 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 771 | 0.160 |
Why?
|
| Herpesviridae | 1 | 2020 | 15 | 0.160 |
Why?
|
| Receptors, IgG | 1 | 2020 | 41 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 726 | 0.160 |
Why?
|
| Registries | 4 | 2018 | 885 | 0.160 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2019 | 48 | 0.160 |
Why?
|
| Zimbabwe | 3 | 2025 | 3 | 0.160 |
Why?
|
| Quality Improvement | 4 | 2018 | 455 | 0.160 |
Why?
|
| Survival Rate | 3 | 2017 | 859 | 0.160 |
Why?
|
| Crosses, Genetic | 1 | 2019 | 110 | 0.160 |
Why?
|
| Time Factors | 6 | 2017 | 3725 | 0.150 |
Why?
|
| Research Design | 1 | 2023 | 583 | 0.150 |
Why?
|
| HLA-DR3 Antigen | 1 | 2019 | 7 | 0.150 |
Why?
|
| Geography | 4 | 2021 | 37 | 0.150 |
Why?
|
| ROC Curve | 1 | 2019 | 288 | 0.150 |
Why?
|
| Leukapheresis | 2 | 2016 | 11 | 0.150 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 219 | 0.150 |
Why?
|
| Calcium Gluconate | 1 | 2018 | 6 | 0.140 |
Why?
|
| Case-Control Studies | 5 | 2025 | 1131 | 0.140 |
Why?
|
| Emergency Treatment | 2 | 2016 | 58 | 0.140 |
Why?
|
| Health Policy | 2 | 2018 | 195 | 0.140 |
Why?
|
| Benchmarking | 2 | 2023 | 134 | 0.140 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2018 | 32 | 0.140 |
Why?
|
| Fetal Blood | 1 | 2018 | 73 | 0.140 |
Why?
|
| Piperazines | 3 | 2025 | 87 | 0.140 |
Why?
|
| Longitudinal Studies | 4 | 2023 | 1272 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 183 | 0.140 |
Why?
|
| Retrospective Studies | 10 | 2022 | 6741 | 0.140 |
Why?
|
| Wounds, Gunshot | 1 | 2018 | 56 | 0.140 |
Why?
|
| Erythrocyte Transfusion | 2 | 2017 | 76 | 0.140 |
Why?
|
| Mali | 1 | 2017 | 2 | 0.140 |
Why?
|
| Seroepidemiologic Studies | 3 | 2023 | 53 | 0.140 |
Why?
|
| Peptide Library | 1 | 2018 | 37 | 0.140 |
Why?
|
| Tranexamic Acid | 1 | 2017 | 7 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 735 | 0.140 |
Why?
|
| Antifibrinolytic Agents | 1 | 2017 | 16 | 0.140 |
Why?
|
| DNA Copy Number Variations | 3 | 2024 | 71 | 0.140 |
Why?
|
| Molecular Sequence Data | 4 | 2015 | 1999 | 0.140 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 329 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2017 | 21 | 0.140 |
Why?
|
| Endotoxins | 1 | 2018 | 82 | 0.130 |
Why?
|
| Antipruritics | 1 | 2017 | 3 | 0.130 |
Why?
|
| Placenta Diseases | 1 | 2017 | 9 | 0.130 |
Why?
|
| Placenta | 1 | 2018 | 61 | 0.130 |
Why?
|
| Firearms | 1 | 2018 | 71 | 0.130 |
Why?
|
| Infant, Low Birth Weight | 1 | 2017 | 60 | 0.130 |
Why?
|
| Mutation Rate | 1 | 2017 | 23 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2017 | 356 | 0.130 |
Why?
|
| Cholecalciferol | 1 | 2017 | 28 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2017 | 64 | 0.130 |
Why?
|
| Polyadenylation | 1 | 2017 | 51 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 210 | 0.130 |
Why?
|
| Violence | 1 | 2018 | 170 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.130 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2017 | 65 | 0.130 |
Why?
|
| Spatial Analysis | 3 | 2023 | 12 | 0.130 |
Why?
|
| Epitopes | 1 | 2018 | 292 | 0.130 |
Why?
|
| Pre-Eclampsia | 1 | 2017 | 69 | 0.130 |
Why?
|
| Loiasis | 1 | 2016 | 1 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 207 | 0.130 |
Why?
|
| Babesia microti | 1 | 2016 | 7 | 0.120 |
Why?
|
| Babesiosis | 1 | 2016 | 12 | 0.120 |
Why?
|
| Head Injuries, Penetrating | 1 | 2016 | 5 | 0.120 |
Why?
|
| Tourniquets | 1 | 2016 | 6 | 0.120 |
Why?
|
| Groin | 1 | 2016 | 15 | 0.120 |
Why?
|
| Immunization, Passive | 3 | 2021 | 96 | 0.120 |
Why?
|
| Manikins | 1 | 2016 | 21 | 0.120 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2016 | 29 | 0.120 |
Why?
|
| Chemoprevention | 1 | 2016 | 41 | 0.120 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 187 | 0.120 |
Why?
|
| Aged | 8 | 2026 | 14663 | 0.120 |
Why?
|
| Organizational Innovation | 2 | 2013 | 82 | 0.120 |
Why?
|
| Semen | 1 | 2016 | 48 | 0.120 |
Why?
|
| Blast Injuries | 1 | 2016 | 5 | 0.120 |
Why?
|
| Ebolavirus | 1 | 2016 | 39 | 0.120 |
Why?
|
| Microbiota | 1 | 2018 | 136 | 0.120 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 180 | 0.120 |
Why?
|
| Organizational Policy | 1 | 2016 | 52 | 0.120 |
Why?
|
| Laparotomy | 1 | 2016 | 54 | 0.120 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 161 | 0.120 |
Why?
|
| Splenectomy | 1 | 2015 | 41 | 0.120 |
Why?
|
| Mass Casualty Incidents | 2 | 2012 | 33 | 0.120 |
Why?
|
| Biota | 1 | 2015 | 3 | 0.120 |
Why?
|
| General Surgery | 1 | 2018 | 214 | 0.120 |
Why?
|
| Simulation Training | 1 | 2016 | 66 | 0.120 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2015 | 12 | 0.120 |
Why?
|
| Drug Monitoring | 2 | 2015 | 206 | 0.110 |
Why?
|
| Postoperative Care | 1 | 2015 | 124 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 676 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2022 | 3318 | 0.110 |
Why?
|
| Rh Isoimmunization | 1 | 2014 | 1 | 0.110 |
Why?
|
| Sexual Behavior | 1 | 2016 | 195 | 0.110 |
Why?
|
| Ixodes | 1 | 2015 | 34 | 0.110 |
Why?
|
| Isoantibodies | 1 | 2014 | 35 | 0.110 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2016 | 118 | 0.110 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 70 | 0.110 |
Why?
|
| Renal Dialysis | 1 | 2016 | 195 | 0.110 |
Why?
|
| Venous Thromboembolism | 1 | 2016 | 147 | 0.110 |
Why?
|
| Sirolimus | 1 | 2015 | 94 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 122 | 0.110 |
Why?
|
| Phylogeography | 1 | 2014 | 6 | 0.110 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2016 | 99 | 0.110 |
Why?
|
| Hemorrhage | 1 | 2016 | 275 | 0.110 |
Why?
|
| Analgesics | 1 | 2015 | 102 | 0.110 |
Why?
|
| RNA Interference | 1 | 2017 | 621 | 0.110 |
Why?
|
| Erythrocytes | 1 | 2015 | 150 | 0.110 |
Why?
|
| Biomarkers | 2 | 2024 | 1431 | 0.100 |
Why?
|
| Counseling | 1 | 2016 | 370 | 0.100 |
Why?
|
| 3' Untranslated Regions | 1 | 2014 | 94 | 0.100 |
Why?
|
| Sickle Cell Trait | 1 | 2013 | 8 | 0.100 |
Why?
|
| Interleukin-10 | 1 | 2014 | 161 | 0.100 |
Why?
|
| Regional Medical Programs | 1 | 2012 | 8 | 0.100 |
Why?
|
| Blood Component Transfusion | 1 | 2012 | 11 | 0.100 |
Why?
|
| Arm Injuries | 1 | 2012 | 12 | 0.100 |
Why?
|
| Leg Injuries | 1 | 2012 | 16 | 0.100 |
Why?
|
| Africa, Central | 2 | 2022 | 3 | 0.100 |
Why?
|
| Mobile Health Units | 1 | 2012 | 13 | 0.100 |
Why?
|
| Mosquito Control | 2 | 2022 | 8 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2014 | 325 | 0.100 |
Why?
|
| Compartment Syndromes | 1 | 2012 | 13 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 381 | 0.100 |
Why?
|
| Pain Management | 1 | 2015 | 169 | 0.100 |
Why?
|
| Risk | 3 | 2021 | 379 | 0.090 |
Why?
|
| Models, Biological | 1 | 2017 | 1187 | 0.090 |
Why?
|
| Mefloquine | 2 | 2025 | 4 | 0.090 |
Why?
|
| Infant, Newborn | 3 | 2025 | 1375 | 0.090 |
Why?
|
| Bacteria | 1 | 2015 | 317 | 0.090 |
Why?
|
| Resuscitation | 1 | 2012 | 74 | 0.090 |
Why?
|
| Cameroon | 2 | 2025 | 3 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 226 | 0.090 |
Why?
|
| Quinolines | 2 | 2025 | 48 | 0.090 |
Why?
|
| Proguanil | 2 | 2022 | 6 | 0.090 |
Why?
|
| Risk Factors | 4 | 2025 | 5341 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 462 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 685 | 0.090 |
Why?
|
| Emergency Medical Services | 1 | 2015 | 267 | 0.090 |
Why?
|
| Africa South of the Sahara | 2 | 2024 | 21 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 2 | 2024 | 318 | 0.080 |
Why?
|
| Travel | 2 | 2021 | 44 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2023 | 209 | 0.080 |
Why?
|
| Antibodies, Viral | 2 | 2023 | 329 | 0.080 |
Why?
|
| Principal Component Analysis | 2 | 2020 | 62 | 0.080 |
Why?
|
| Cytochromes b | 2 | 2021 | 4 | 0.070 |
Why?
|
| Atovaquone | 2 | 2021 | 5 | 0.070 |
Why?
|
| Risk Assessment | 4 | 2020 | 2048 | 0.070 |
Why?
|
| Blood Donors | 2 | 2020 | 22 | 0.070 |
Why?
|
| Species Specificity | 2 | 2016 | 334 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2021 | 5696 | 0.070 |
Why?
|
| Citric Acid | 2 | 2018 | 20 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2017 | 3068 | 0.070 |
Why?
|
| Sequence Alignment | 2 | 2005 | 302 | 0.070 |
Why?
|
| Viral Load | 2 | 2021 | 233 | 0.070 |
Why?
|
| RNA, Ribosomal, 18S | 1 | 2026 | 8 | 0.060 |
Why?
|
| Climate Change | 1 | 2026 | 25 | 0.060 |
Why?
|
| Quinine | 1 | 2025 | 4 | 0.060 |
Why?
|
| History, 21st Century | 2 | 2017 | 176 | 0.060 |
Why?
|
| Cities | 1 | 2025 | 31 | 0.060 |
Why?
|
| Centromere | 2 | 2004 | 41 | 0.060 |
Why?
|
| Transcription, Genetic | 2 | 2016 | 884 | 0.060 |
Why?
|
| Peru | 1 | 2024 | 14 | 0.060 |
Why?
|
| Genetic Association Studies | 1 | 2025 | 120 | 0.060 |
Why?
|
| Exons | 2 | 2005 | 201 | 0.060 |
Why?
|
| Metagenomics | 1 | 2024 | 28 | 0.060 |
Why?
|
| South Sudan | 1 | 2024 | 1 | 0.060 |
Why?
|
| Ethanolamines | 1 | 2024 | 18 | 0.050 |
Why?
|
| Dihydropteroate Synthase | 1 | 2024 | 6 | 0.050 |
Why?
|
| Rats, Inbred BN | 1 | 2004 | 26 | 0.050 |
Why?
|
| Burkina Faso | 1 | 2024 | 2 | 0.050 |
Why?
|
| Health Surveys | 1 | 2025 | 314 | 0.050 |
Why?
|
| Health Facilities | 1 | 2024 | 43 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2025 | 272 | 0.050 |
Why?
|
| Receptors, KIR3DS1 | 1 | 2023 | 3 | 0.050 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2023 | 6 | 0.050 |
Why?
|
| Recurrence | 2 | 2016 | 652 | 0.050 |
Why?
|
| Refugees | 1 | 2024 | 70 | 0.050 |
Why?
|
| Microdissection | 1 | 2023 | 7 | 0.050 |
Why?
|
| Ligases | 1 | 2023 | 28 | 0.050 |
Why?
|
| Formaldehyde | 1 | 2023 | 31 | 0.050 |
Why?
|
| Informatics | 1 | 2023 | 11 | 0.050 |
Why?
|
| Nucleocapsid Proteins | 1 | 2023 | 36 | 0.050 |
Why?
|
| Gabon | 1 | 2022 | 1 | 0.050 |
Why?
|
| Ethylenediamines | 1 | 2022 | 2 | 0.050 |
Why?
|
| Asparagine | 1 | 2022 | 25 | 0.050 |
Why?
|
| Quality Control | 2 | 2012 | 74 | 0.050 |
Why?
|
| Forests | 1 | 2022 | 7 | 0.050 |
Why?
|
| Rituximab | 1 | 2023 | 89 | 0.050 |
Why?
|
| Sulfones | 1 | 2022 | 41 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2023 | 102 | 0.050 |
Why?
|
| Animals, Domestic | 1 | 2022 | 15 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 56 | 0.050 |
Why?
|
| Cats | 1 | 2022 | 89 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2022 | 136 | 0.050 |
Why?
|
| Genes, Duplicate | 1 | 2001 | 2 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2001 | 17 | 0.050 |
Why?
|
| Virus Replication | 1 | 2023 | 324 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2023 | 116 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2023 | 458 | 0.050 |
Why?
|
| Consensus | 1 | 2023 | 185 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2001 | 65 | 0.040 |
Why?
|
| Cattle | 1 | 2022 | 316 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2012 | 587 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2001 | 167 | 0.040 |
Why?
|
| Base Sequence | 2 | 2014 | 1335 | 0.040 |
Why?
|
| Dogs | 1 | 2022 | 332 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 463 | 0.040 |
Why?
|
| Genome, Human | 1 | 2003 | 240 | 0.040 |
Why?
|
| Hydrodynamics | 1 | 2021 | 37 | 0.040 |
Why?
|
| Aerosols | 1 | 2021 | 47 | 0.040 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2020 | 10 | 0.040 |
Why?
|
| Pressure | 1 | 2021 | 78 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2022 | 192 | 0.040 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2020 | 19 | 0.040 |
Why?
|
| Investigational New Drug Application | 1 | 2020 | 1 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 1622 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2023 | 401 | 0.040 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family | 1 | 2020 | 6 | 0.040 |
Why?
|
| Geographic Information Systems | 1 | 2020 | 24 | 0.040 |
Why?
|
| CD56 Antigen | 1 | 2020 | 17 | 0.040 |
Why?
|
| Protein Binding | 2 | 2016 | 1619 | 0.040 |
Why?
|
| Islands | 1 | 2020 | 2 | 0.040 |
Why?
|
| Haploidy | 1 | 2020 | 11 | 0.040 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2019 | 6 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2023 | 1164 | 0.040 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2019 | 14 | 0.040 |
Why?
|
| Genes, Protozoan | 1 | 2019 | 14 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 91 | 0.040 |
Why?
|
| Environment | 1 | 2020 | 123 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 122 | 0.040 |
Why?
|
| Gene Library | 1 | 2020 | 102 | 0.040 |
Why?
|
| Mice | 3 | 2023 | 10994 | 0.040 |
Why?
|
| Demography | 1 | 2020 | 174 | 0.040 |
Why?
|
| Adenosine Triphosphatases | 1 | 2021 | 256 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2020 | 234 | 0.040 |
Why?
|
| DNA | 1 | 2024 | 844 | 0.040 |
Why?
|
| Homozygote | 1 | 2019 | 124 | 0.040 |
Why?
|
| Chicago | 1 | 2018 | 26 | 0.040 |
Why?
|
| Mutagenesis | 2 | 2013 | 133 | 0.040 |
Why?
|
| Cultural Characteristics | 1 | 2018 | 38 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2019 | 98 | 0.040 |
Why?
|
| Philippines | 1 | 2018 | 7 | 0.040 |
Why?
|
| Peptides | 1 | 2022 | 590 | 0.040 |
Why?
|
| Schistosomiasis | 1 | 2018 | 5 | 0.040 |
Why?
|
| Bacterial Translocation | 1 | 2018 | 10 | 0.040 |
Why?
|
| Social Isolation | 1 | 2018 | 37 | 0.040 |
Why?
|
| Hookworm Infections | 1 | 2018 | 11 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2022 | 364 | 0.040 |
Why?
|
| Fetal Growth Retardation | 1 | 2018 | 18 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 759 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 361 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2020 | 668 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2021 | 482 | 0.040 |
Why?
|
| Community-Based Participatory Research | 1 | 2018 | 56 | 0.040 |
Why?
|
| Safety | 1 | 2018 | 145 | 0.030 |
Why?
|
| Peptidomimetics | 1 | 2018 | 7 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 176 | 0.030 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2018 | 7 | 0.030 |
Why?
|
| Surgeons | 1 | 2021 | 182 | 0.030 |
Why?
|
| Filgrastim | 1 | 2017 | 8 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2017 | 15 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 572 | 0.030 |
Why?
|
| Benin | 1 | 2017 | 2 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2020 | 265 | 0.030 |
Why?
|
| Gestational Age | 1 | 2018 | 191 | 0.030 |
Why?
|
| Calcium Phosphates | 1 | 2017 | 8 | 0.030 |
Why?
|
| Health Resources | 1 | 2018 | 94 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 125 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 47 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 756 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2017 | 201 | 0.030 |
Why?
|
| Liberia | 1 | 2016 | 11 | 0.030 |
Why?
|
| International Cooperation | 1 | 2017 | 90 | 0.030 |
Why?
|
| Carrier State | 1 | 2016 | 18 | 0.030 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2016 | 29 | 0.030 |
Why?
|
| Microfilariae | 1 | 2016 | 4 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2016 | 130 | 0.030 |
Why?
|
| Condoms | 1 | 2016 | 48 | 0.030 |
Why?
|
| Zoonoses | 1 | 2016 | 9 | 0.030 |
Why?
|
| Serum Albumin, Human | 1 | 2016 | 7 | 0.030 |
Why?
|
| Cell Line | 1 | 2021 | 2057 | 0.030 |
Why?
|
| Spinal Puncture | 1 | 2016 | 16 | 0.030 |
Why?
|
| Cerebrospinal Fluid | 1 | 2016 | 24 | 0.030 |
Why?
|
| Azithromycin | 1 | 2016 | 32 | 0.030 |
Why?
|
| Gene Expression | 1 | 2019 | 851 | 0.030 |
Why?
|
| Ribosomal Proteins | 1 | 2016 | 44 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1570 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2016 | 116 | 0.030 |
Why?
|
| Intracranial Hemorrhages | 1 | 2016 | 68 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2016 | 239 | 0.030 |
Why?
|
| DNA, Ribosomal | 1 | 2015 | 32 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2023 | 2237 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 316 | 0.030 |
Why?
|
| Mental Health | 1 | 2018 | 372 | 0.030 |
Why?
|
| Glucose | 1 | 2018 | 471 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2015 | 99 | 0.030 |
Why?
|
| Live Birth | 1 | 2015 | 21 | 0.030 |
Why?
|
| Pulmonary Ventilation | 1 | 2015 | 38 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2013 | 1160 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 115 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2016 | 112 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 182 | 0.030 |
Why?
|
| Liver Failure | 1 | 2015 | 18 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2015 | 97 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2017 | 239 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 1270 | 0.030 |
Why?
|
| Morphine | 1 | 2015 | 59 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2014 | 32 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2016 | 285 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2015 | 125 | 0.030 |
Why?
|
| Occupational Injuries | 1 | 2015 | 36 | 0.030 |
Why?
|
| Ketamine | 1 | 2015 | 38 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 529 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 449 | 0.030 |
Why?
|
| Dyspnea | 1 | 2015 | 124 | 0.030 |
Why?
|
| Biostatistics | 1 | 2014 | 5 | 0.030 |
Why?
|
| Fentanyl | 1 | 2015 | 75 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 788 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 945 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 69 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2016 | 175 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2015 | 104 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2015 | 268 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 2015 | 116 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 2014 | 173 | 0.030 |
Why?
|
| Korean War | 1 | 2013 | 1 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2018 | 709 | 0.030 |
Why?
|
| Vietnam Conflict | 1 | 2013 | 26 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 1682 | 0.030 |
Why?
|
| Retroelements | 2 | 2004 | 44 | 0.030 |
Why?
|
| Hospitals | 1 | 2016 | 390 | 0.030 |
Why?
|
| DNA Primers | 1 | 2013 | 295 | 0.020 |
Why?
|
| Shock, Hemorrhagic | 1 | 2012 | 19 | 0.020 |
Why?
|
| Forecasting | 1 | 2013 | 233 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2015 | 517 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 457 | 0.020 |
Why?
|
| Sex Factors | 1 | 2015 | 980 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2013 | 235 | 0.020 |
Why?
|
| Evidence-Based Practice | 1 | 2012 | 84 | 0.020 |
Why?
|
| Professional Competence | 1 | 2012 | 93 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 519 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 412 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2016 | 870 | 0.020 |
Why?
|
| Binding Sites | 1 | 2014 | 914 | 0.020 |
Why?
|
| Triage | 1 | 2012 | 128 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2012 | 490 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2013 | 785 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 1597 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2012 | 856 | 0.020 |
Why?
|
| Curriculum | 1 | 2012 | 607 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 1301 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2005 | 81 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 5528 | 0.010 |
Why?
|
| Base Composition | 1 | 2004 | 31 | 0.010 |
Why?
|
| RNA Splice Sites | 1 | 2004 | 23 | 0.010 |
Why?
|
| Chromosomes, Mammalian | 1 | 2004 | 34 | 0.010 |
Why?
|
| Telomere | 1 | 2004 | 53 | 0.010 |
Why?
|
| DNA, Mitochondrial | 1 | 2004 | 88 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2004 | 102 | 0.010 |
Why?
|
| Lemur | 1 | 2003 | 1 | 0.010 |
Why?
|
| Pongo pygmaeus | 1 | 2003 | 2 | 0.010 |
Why?
|
| RNA, Untranslated | 1 | 2004 | 103 | 0.010 |
Why?
|
| Papio | 1 | 2003 | 21 | 0.010 |
Why?
|
| DNA Transposable Elements | 1 | 2004 | 140 | 0.010 |
Why?
|
| CpG Islands | 1 | 2004 | 216 | 0.010 |
Why?
|
| Point Mutation | 1 | 2003 | 165 | 0.010 |
Why?
|
| Internet | 1 | 2005 | 467 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 2005 | 0.010 |
Why?
|